Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Dyne Therapeutics, Inc. (DYN)

7.94   -1.02 (-11.38%) 10-02 16:00
Open: 9.2 Pre. Close: 8.96
High: 8.88 Low: 7.83
Volume: 469,740 Market Cap: 485(M)

Technical analysis

as of: 2023-10-02 4:19:30 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 12.26     One year: 14.19
Support: Support1: 7.82    Support2: 6.51
Resistance: Resistance1: 10.49    Resistance2: 12.14
Pivot: 9.14
Moving Average: MA(5): 8.65     MA(20): 9.71
MA(100): 11.41     MA(250): 11.75
MACD: MACD(12,26): -0.7     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 12.2     %D(3): 12
RSI: RSI(14): 30.2
52-week: High: 15.6  Low: 7.82
Average Vol(K): 3-Month: 417 (K)  10-Days: 520 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ DYN ] has closed below the lower bollinger band by 9.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.09 - 9.12 9.12 - 9.16
Low: 8.56 - 8.6 8.6 - 8.64
Close: 8.9 - 8.96 8.96 - 9.02

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Headline News

Fri, 29 Sep 2023
Dyne Therapeutics, Inc. (NYSE:DYN) Receives Consensus ... - MarketBeat

Thu, 28 Sep 2023
Dyne Therapeutics to Present at October Investor Conferences - GlobeNewswire

Mon, 18 Sep 2023
Should You Hold Dyne Therapeutics Inc (DYN) Stock Monday? - InvestorsObserver

Tue, 05 Sep 2023
Should You Add Dyne Therapeutics Inc (DYN) Stock to Your Portfolio Tuesday? - InvestorsObserver

Tue, 29 Aug 2023
Insider Transactions and New Acquisition Shape Dyne Therapeutics ... - Best Stocks

Mon, 28 Aug 2023
Should You Buy Dyne Therapeutics Inc (DYN) Stock on Monday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 40 (M)
% Held by Insiders 1.3 (%)
% Held by Institutions 104.9 (%)
Shares Short 5,630 (K)
Shares Short P.Month 5,190 (K)

Stock Financials

EPS -3.22
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.39
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -41.2
Return on Equity (ttm) -76.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.17
Qtrly Earnings Growth 0
Operating Cash Flow -175 (M)
Levered Free Cash Flow -109 (M)

Stock Valuations

PE Ratio -2.48
PEG Ratio 0
Price to Book value 2.34
Price to Sales 0
Price to Cash Flow -2.78

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.